Peringatan Keamanan

Patients experiencing an overdose of iron may present with nausea, vomiting, abdominal pain, diarrhea, fluid and blood loss, hypovolemia, hematemesis, perforation, and peritonitis.^A214169 Mild overdoses can be treated with symptomatic and supportive measures.^A214169 More severe overdoses may require more intense treatment including chelating agents, and intravenous fluids.^A214169 Activated charcoal is not expected to be beneficial in the case of iron overdose.^A214169

The acute oral LD₅₀ in rats is 1487mg/kg and in mice is 1520mg/kg.^L14291 The acute dermal LD₅₀ in rabbits is 2000mg/kg.^L14291

Tetraferric tricitrate decahydrate

DB14520

small molecule approved

Deskripsi

Tetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease.^A25965

Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014.^L9926

Struktur Molekul 2D

Berat 967.803

Wujud solid

Peta Jejaring Molekuler

Obat Target Gen Interaksi Enzim Transporter Carrier

Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

1. Pendahuluan & Konsep

Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).

2. Sumber Data (Validasi)

Data Obat: Diekstraksi dari elemen drugbank-id dan name pada skema XML DrugBank.
Target Protein: Diambil dari elemen targets/target yang memuat polipeptida sasaran.
Genetik: Disinkronisasi dari sub-elemen gene-name dan varian snp-effects.
Genetik: Jumlah titik node dibatasi pada maksimal 10 (Slice=10) interaksi untuk menghindari tumpukan data.

3. Algoritma Visualisasi

Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.

4. Legenda Visual

Obat Utama (Pusat Analisis)

Target Protein (Mekanisme)

Gen (Faktor Genetik)

Metode ini mendukung analisis Precision Medicine dan evaluasi risiko Drug-Drug Interaction (DDI).

Profil Farmakokinetik

Waktu Paruh (Half-Life) -

Volume Distribusi -

Klirens (Clearance) Data regarding the clearance of iron is not readily available. However, iron loss due to exfoliation of epithelial cells is approximately 1mg/day.[A32514]

Absorpsi

Ferric iron has been shown to have inferior bioavailability to ferrous iron preparations.^A214178 Tetraferric tricitrate decahydrate has 19% the bioavailability of ferrous ascorbate.^A214178

Metabolisme

Ferric cation is converted to ferrous iron by duodenal cytochrome B reductase.^A32525 The heavy chain ferritin may also convert ferric iron to ferrous ironA32525,A204311

Rute Eliminasi

Unabsorbed oral Tetraferric tricitrate decahydrate is eliminated in the feces.^L9926 The absorbed iron from Tetraferric tricitrate decahydrate is generally not eliminated from the body by any route other than blood loss and exfoliation of epithelial cells.A32514,L9926

Interaksi Makanan

1 Data

1. Take with food.

Interaksi Obat

127 Data

Moxifloxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Grepafloxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Enoxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pefloxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ciprofloxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Trovafloxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Nalidixic acid	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Nalidixic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Rosoxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cinoxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Lomefloxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Gatifloxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Norfloxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Levofloxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Gemifloxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ofloxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sparfloxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Temafloxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Fleroxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Technetium Tc-99m ciprofloxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Technetium Tc-99m ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Garenoxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Nemonoxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Flumequine	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Enrofloxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Enrofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Orbifloxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sarafloxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Sarafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Difloxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Difloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pazufloxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Prulifloxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Delafloxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Delafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sitafloxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Oxolinic acid	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Rufloxacin	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pipemidic acid	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dimercaprol	Dimercaprol may increase the nephrotoxic activities of Tetraferric tricitrate decahydrate.
Cefdinir	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Cefdinir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Deferiprone	The serum concentration of Deferiprone can be decreased when it is combined with Tetraferric tricitrate decahydrate.
Dolutegravir	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Dolutegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Eltrombopag	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy.
Levodopa	The bioavailability of Levodopa can be decreased when combined with Tetraferric tricitrate decahydrate.
Levothyroxine	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methyldopa	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Methyldopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
Penicillamine	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Penicillamine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Lipoic acid	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Lipoic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Doxycycline	Doxycycline can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Lymecycline	Lymecycline can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Clomocycline	Clomocycline can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Oxytetracycline	Oxytetracycline can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Demeclocycline	Demeclocycline can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Tetracycline	Tetracycline can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Metacycline	Metacycline can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Minocycline	Minocycline can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sarecycline	Sarecycline can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Omadacycline	Omadacycline can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Penimepicycline	Penimepicycline can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Triethylenetetramine	Triethylenetetramine can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pancrelipase	Pancrelipase can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium oxide	Magnesium oxide can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sodium bicarbonate	Sodium bicarbonate can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum hydroxide	Aluminum hydroxide can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium carbonate	Calcium carbonate can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magaldrate	Magaldrate can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium hydroxide	Magnesium hydroxide can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium trisilicate	Magnesium trisilicate can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium carbonate	Magnesium carbonate can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium silicate	Magnesium silicate can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium acetoacetate	Aluminium acetoacetate can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Hydrotalcite	Hydrotalcite can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium peroxide	Magnesium peroxide can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Almasilate	Almasilate can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium glycinate	Aluminium glycinate can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aloglutamol	Aloglutamol can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium silicate	Calcium silicate can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium phosphate	Aluminium phosphate can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pantoprazole	Pantoprazole can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Lansoprazole	Lansoprazole can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Esomeprazole	Esomeprazole can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Rabeprazole	Rabeprazole can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dexlansoprazole	Dexlansoprazole can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dexrabeprazole	Dexrabeprazole can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sodium zirconium cyclosilicate	Sodium zirconium cyclosilicate can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Vonoprazan	Vonoprazan can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Olanzapine	Olanzapine can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cimetidine	Cimetidine can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Nizatidine	Nizatidine can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ranitidine	Ranitidine can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Famotidine	Famotidine can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methantheline	Methantheline can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Promethazine	Promethazine can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Doxepin	Doxepin can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Asenapine	Asenapine can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Metiamide	Metiamide can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Roxatidine acetate	Roxatidine acetate can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Lafutidine	Lafutidine can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Lavoltidine	Lavoltidine can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Niperotidine	Niperotidine can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Epinastine	Epinastine can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pamidronic acid	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Zoledronic acid	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Alendronic acid	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ibandronate	Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.

Target Protein

Transferrin receptor protein 1 TFRC

Iron(3+)-hydroxamate-binding protein FhuD fhuD

Referensi & Sumber

Artikel (PubMed)

PMID: 24778671
Abbaspour N, Hurrell R, Kelishadi R: Review on iron and its importance for human health. J Res Med Sci. 2014 Feb;19(2):164-74.
PMID: 25053935
Waldvogel-Abramowski S, Waeber G, Gassner C, Buser A, Frey BM, Favrat B, Tissot JD: Physiology of iron metabolism. Transfus Med Hemother. 2014 Jun;41(3):213-21. doi: 10.1159/000362888. Epub 2014 May 12.
PMID: 23548912
Pfaffen S, Abdulqadir R, Le Brun NE, Murphy ME: Mechanism of ferrous iron binding and oxidation by ferritin from a pennate diatom. J Biol Chem. 2013 May 24;288(21):14917-25. doi: 10.1074/jbc.M113.454496. Epub 2013 Apr 2.
PMID: 29083637
Yuen HW, Becker W: Iron Toxicity .
PMID: 1174047
Heinrich HC: Bioavailability of trivalent iron in oral iron preparations. Therapeutic efficacy and iron absorption from simple ferric compounds and high- or low-molecular weight ferric hydroxide-carbohydrate complexes. Arzneimittelforschung. 1975 Mar;25(3):420-6.
PMID: 25987821
Pennoyer A, Bridgeman MB: Ferric citrate (auryxia) for the treatment of hyperphosphatemia. P T. 2015 May;40(5):329-39.

Link

Contoh Produk & Brand

Produk: 2 • International brands: 0

Produk

Auryxia

Tablet, film coated • 210 mg/1 • Oral • US • Approved
Maxine Vitamin and Mineral Supplement

Tablet • - • Oral • Canada • OTC • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.